APLS - Apellis Pharmaceuticals, Inc.

QQQ $ 610.60 $ -0.16 (-0.03 %)

DIA $ 469.20 $ 2.20 (0.47 %)

SPY $ 671.26 $ -0.01 (0 %)

TLT $ 92.04 $ 0.45 (0.49 %)

GLD $ 378.57 $ -25.91 (-6.43 %)

Previous Close

$ 28.31

Open

$ 26.73

Bid

$ 26.59 x 3

Ask

$ 28.50 x 50

Day's Range

$ 26.64 - $ 28.48

52 Week Range

$ 16.10 - $ 35.72

Volume

3,023,728

Average Volume

Market Cap

3.58B

Beta (5Y Monthly)

$ 0.84

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	07-31-2025	06-30-2025	10-Q
2	05-07-2025	03-31-2025	10-Q
3	02-28-2025	01-01-1970	10-K
4	11-05-2024	09-30-2024	10-Q
5	08-01-2024	06-30-2024	10-Q
6	05-07-2024	03-31-2024	10-Q
7	02-27-2024	12-31-2023	10-K
8	11-01-2023	09-30-2023	10-Q
9	07-31-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	02-21-2023	12-31-2022	10-K
12	11-07-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	02-28-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	04-28-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-02-2020	09-30-2020	10-Q
21	07-30-2020	06-30-2020	10-Q
22	04-29-2020	03-31-2020	10-Q
23	02-27-2020	12-31-2019	10-K
24	11-05-2019	09-30-2019	10-Q
25	07-31-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	02-26-2019	12-31-2018	10-K
28	11-13-2018	09-30-2018	10-Q
29	07-31-2018	06-30-2018	10-Q
30	04-30-2018	03-31-2018	10-Q
31	03-19-2018	12-31-2017	10-K
32	12-20-2017	09-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Apellis Highlights New Phase 3 Data Showin...
10/20/2025 11:13:52

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced new data from the open-label period of the Phase 3 VALIANT study th...

Expert Outlook: Apellis Pharmaceuticals Th...
10/15/2025 22:01:52

Wells Fargo Upgrades Apellis Pharmaceutica...
10/15/2025 12:44:12

Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight and raises ...

12 Analysts Assess Apellis Pharmaceuticals...
09/26/2025 18:00:49

During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse...

Goldman Sachs Downgrades Apellis Pharmaceu...
09/26/2025 16:51:18

Goldman Sachs analyst Salveen Richter downgrades Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Sell and lowers the ...

concentrix-posts-downbeat-earnings-joins-legacy-education-kingsoft-cloud-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

Concentrix Posts Downbeat Earnings, Joins ...
09/26/2025 12:04:21

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

why-top-kingwin-shares-are-trading-higher-by-87-here-are-20-stocks-moving-premarket

Why Top KingWin Shares Are Trading Higher ...
09/26/2025 10:25:50

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales ...

JP Morgan Maintains Overweight on Apellis ...
08/04/2025 21:37:17

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target ...

Citigroup Maintains Buy on Apellis Pharmac...
08/01/2025 19:54:12

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target f...

RBC Capital Maintains Sector Perform on Ap...
08/01/2025 15:08:53

RBC Capital analyst Lisa Walter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and raises the price t...

Cantor Fitzgerald Maintains Overweight on ...
08/01/2025 14:11:05

Cantor Fitzgerald analyst Steve Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the p...

Raymond James Maintains Outperform on Apel...
08/01/2025 13:20:10

Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price t...

roblox-carvana-ebay-ch-robinson-worldwide-huntington-ingalls-industries-and-other-big-stocks-moving-higher-on-thursday

Roblox, Carvana, eBay, C.H. Robinson World...
07/31/2025 15:00:57

Apellis Pharmaceuticals Q2 EPS $(0.33) Bea...
07/31/2025 10:56:07

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate ...

Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

Citigroup Maintains Buy on Apellis Pharmac...
07/29/2025 18:24:44

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target f...

fda-approval-for-empaveli-marks-key-milestone-in-apellis-rare-disease-portfolio

FDA Approval For Empaveli Marks Key Milest...
07/29/2025 16:12:25

FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria an...

Trading Halt: Halt status updated at 6:55:...
07/29/2025 10:55:04

Reported Earlier, Apellis Wins FDA Approva...
07/29/2025 07:32:12

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and sub...

Trading Halt: Halted at 5:18:12 p.m. ET - ...
07/28/2025 21:18:17